Capricor Therapeutics CAPR Amortization Or Accretion Of Debt Discount Premium

Other financials

Revenue--100%

Operating income-$36.8M-47.2%

Net income-$33.9M-39.2%

EPS (diluted)-$0.59-11.3%

Cash & equivalents$105.4M+266%

Total debt$14.8M+1,083%

Total equity$278.7M+118%

Total assets$326.3M+112%

Operating cash flow-$29.3M-355%

CapEx$5.1M+472%

Free cash flow-$34.4M-369%

Market cap$1.71B+303%

Enterprise value$1.62B+308%

Operating margin-778.8%-1,038pp

Net margin-736.6%-981pp

FCF margin-563.9%-954pp

Return on equity-56.4%-11.3pp

Debt / equity0.1×0.0×

Current ratio8.4×+1.9×

Reported directly by Capricor Therapeutics in its filing.

Tagged under the XBRL concept capr:AmortizationOrAccretionOfDebtDiscountPremium.

The official record: Capricor Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and see it in context, right in your chat.

What is Capricor Therapeutics's amortization or accretion of debt discount premium?: Capricor Therapeutics (CAPR) reported amortization or accretion of debt discount premium of -$358.63K in Q1 2026.